Data from IRS2 Copy Number Gain, KRAS and BRAF Mutation Status as Predictive Biomarkers for Response to the IGF-1R/IR Inhibitor BMS-754807 in Colorectal Cancer Cell Lines Article Swipe

View

Fei Huang , Han Chang , Ann Greer , Stephen Hillerman , Karen A. Reeves , Warren Hurlburt , John Cogswell , Dharmesh Patel , Zhenhao Qi , Craig Fairchild , Rolf-Peter Ryseck , Tai W. Wong , Friedrich Graf Finckenstein , Jeffrey R. Jackson , Joan M. Carboni ·

YOU? · · 2023 · Open Access · · DOI: https://doi.org/10.1158/1535-7163.c.6537472

Insulin-like growth factor receptor 1 (IGF-1R)–targeting therapies are currently at an important crossroad given the low clinical response rates seen in unselected patients. Predictive biomarkers for patient selection are critical for improving clinical benefit. Coupling in vitro sensitivity testing of BMS-754807, a dual IGF-1R/IR inhibitor, with genomic interrogations in 60 human colorectal cancer cell lines, we identified biomarkers correlated with response to BMS-754807. The results showed that cell lines with BRAF^V600E or KRAS^G13D mutation were resistant, whereas cell lines with wild-type of both KRAS and BRAF were particularly sensitive to BMS-754807 if they have either higher RNA expression levels of IR-A or lower levels of IGFBP6. In addition, the cell lines with KRAS mutations, those with either insulin receptor substrate 2 (IRS2) copy number gain (CNG) or higher IGF-1R expression levels, were more sensitive to the drug. Furthermore, cell lines with IRS2 CNG had higher levels of ligand-stimulated activation of IGF-1R and AKT, suggesting that these cell lines with IGF-IR signaling pathways more actively coupled to AKT signaling are more responsive to IGF-1R/IR inhibition. IRS2 siRNA knockdown reduced IRS2 protein expression levels and decreased sensitivity to BMS-754807, providing evidence for the functional involvement of IRS2 in mediating the drug response. The prevalence of IRS2 CNG in colorectal cancer tumors as measured by qPCR-CNV is approximately 35%. In summary, we identified IRS2 CNG, IGF-1R, IR-A, and IGFBP6 RNA expression levels, and KRAS and BRAF mutational status as candidate predictive biomarkers for response to BMS-754807. This work proposed clinical development opportunities for BMS-754807 in colorectal cancer with patient selection to improve clinical benefit. Mol Cancer Ther; 14(2); 620–30. ©2014 AACR.

Related Topics

Concepts

KRAS Internal medicine Mutation Oncology Biology Medicine Genetics Gene

Metadata

Type: preprint
Language: en
Landing Page: https://doi.org/10.1158/1535-7163.c.6537472
OA Status: gold
Related Works: 10
OpenAlex ID: https://openalex.org/W4392681989

All OpenAlex metadata

Raw OpenAlex JSON

OpenAlex ID: https://openalex.org/W4392681989

Canonical identifier for this work in OpenAlex
DOI: https://doi.org/10.1158/1535-7163.c.6537472

Digital Object Identifier
Title: Data from IRS2 Copy Number Gain, KRAS and BRAF Mutation Status as Predictive Biomarkers for Response to the IGF-1R/IR Inhibitor BMS-754807 in Colorectal Cancer Cell Lines

Work title
Type: preprint

OpenAlex work type
Language: en

Primary language
Publication year: 2023

Year of publication
Publication date: 2023-04-03

Full publication date if available
Authors: Fei Huang, Han Chang, Ann Greer, Stephen Hillerman, Karen A. Reeves, Warren Hurlburt, John Cogswell, Dharmesh Patel, Zhenhao Qi, Craig Fairchild, Rolf-Peter Ryseck, Tai W. Wong, Friedrich Graf Finckenstein, Jeffrey R. Jackson, Joan M. Carboni

List of authors in order
Landing page: https://doi.org/10.1158/1535-7163.c.6537472

Publisher landing page
Open access: Yes

Whether a free full text is available
OA status: gold

Open access status per OpenAlex
OA URL: https://doi.org/10.1158/1535-7163.c.6537472

Direct OA link when available
Concepts: KRAS, Internal medicine, Mutation, Oncology, Biology, Medicine, Genetics, Gene

Top concepts (fields/topics) attached by OpenAlex
Cited by: 0

Total citation count in OpenAlex
Related works (count): 10

Other works algorithmically related by OpenAlex

Full payload

id	https://openalex.org/W4392681989
doi	https://doi.org/10.1158/1535-7163.c.6537472
ids.doi	https://doi.org/10.1158/1535-7163.c.6537472
ids.openalex	https://openalex.org/W4392681989
fwci	0.0
type	preprint
title	Data from <i>IRS2</i> Copy Number Gain, <i>KRAS</i> and <i>BRAF</i> Mutation Status as Predictive Biomarkers for Response to the IGF-1R/IR Inhibitor BMS-754807 in Colorectal Cancer Cell Lines
biblio.issue
biblio.volume
biblio.last_page
biblio.first_page
topics[0].id	https://openalex.org/T11067
topics[0].field.id	https://openalex.org/fields/27
topics[0].field.display_name	Medicine
topics[0].score	0.9811999797821045
topics[0].domain.id	https://openalex.org/domains/4
topics[0].domain.display_name	Health Sciences
topics[0].subfield.id	https://openalex.org/subfields/2730
topics[0].subfield.display_name	Oncology
topics[0].display_name	Colorectal Cancer Treatments and Studies
topics[1].id	https://openalex.org/T10631
topics[1].field.id	https://openalex.org/fields/13
topics[1].field.display_name	Biochemistry, Genetics and Molecular Biology
topics[1].score	0.9388999938964844
topics[1].domain.id	https://openalex.org/domains/1
topics[1].domain.display_name	Life Sciences
topics[1].subfield.id	https://openalex.org/subfields/1306
topics[1].subfield.display_name	Cancer Research
topics[1].display_name	Cancer, Hypoxia, and Metabolism
is_xpac	False
apc_list
apc_paid
concepts[0].id	https://openalex.org/C2781187634
concepts[0].level	4
concepts[0].score	0.7949526309967041
concepts[0].wikidata	https://www.wikidata.org/wiki/Q20969980
concepts[0].display_name	KRAS
concepts[1].id	https://openalex.org/C126322002
concepts[1].level	1
concepts[1].score	0.34850722551345825
concepts[1].wikidata	https://www.wikidata.org/wiki/Q11180
concepts[1].display_name	Internal medicine
concepts[2].id	https://openalex.org/C501734568
concepts[2].level	3
concepts[2].score	0.33809271454811096
concepts[2].wikidata	https://www.wikidata.org/wiki/Q42918
concepts[2].display_name	Mutation
concepts[3].id	https://openalex.org/C143998085
concepts[3].level	1
concepts[3].score	0.33802294731140137
concepts[3].wikidata	https://www.wikidata.org/wiki/Q162555
concepts[3].display_name	Oncology
concepts[4].id	https://openalex.org/C86803240
concepts[4].level	0
concepts[4].score	0.3287461996078491
concepts[4].wikidata	https://www.wikidata.org/wiki/Q420
concepts[4].display_name	Biology
concepts[5].id	https://openalex.org/C71924100
concepts[5].level	0
concepts[5].score	0.28673648834228516
concepts[5].wikidata	https://www.wikidata.org/wiki/Q11190
concepts[5].display_name	Medicine
concepts[6].id	https://openalex.org/C54355233
concepts[6].level	1
concepts[6].score	0.24031850695610046
concepts[6].wikidata	https://www.wikidata.org/wiki/Q7162
concepts[6].display_name	Genetics
concepts[7].id	https://openalex.org/C104317684
concepts[7].level	2
concepts[7].score	0.11947140097618103
concepts[7].wikidata	https://www.wikidata.org/wiki/Q7187
concepts[7].display_name	Gene
keywords[0].id	https://openalex.org/keywords/kras
keywords[0].score	0.7949526309967041
keywords[0].display_name	KRAS
keywords[1].id	https://openalex.org/keywords/internal-medicine
keywords[1].score	0.34850722551345825
keywords[1].display_name	Internal medicine
keywords[2].id	https://openalex.org/keywords/mutation
keywords[2].score	0.33809271454811096
keywords[2].display_name	Mutation
keywords[3].id	https://openalex.org/keywords/oncology
keywords[3].score	0.33802294731140137
keywords[3].display_name	Oncology
keywords[4].id	https://openalex.org/keywords/biology
keywords[4].score	0.3287461996078491
keywords[4].display_name	Biology
keywords[5].id	https://openalex.org/keywords/medicine
keywords[5].score	0.28673648834228516
keywords[5].display_name	Medicine
keywords[6].id	https://openalex.org/keywords/genetics
keywords[6].score	0.24031850695610046
keywords[6].display_name	Genetics
keywords[7].id	https://openalex.org/keywords/gene
keywords[7].score	0.11947140097618103
keywords[7].display_name	Gene
language	en
locations[0].id	doi:10.1158/1535-7163.c.6537472
locations[0].is_oa	True
locations[0].source
locations[0].license	cc-by
locations[0].pdf_url
locations[0].version	acceptedVersion
locations[0].raw_type	posted-content
locations[0].license_id	https://openalex.org/licenses/cc-by
locations[0].is_accepted	True
locations[0].is_published	False
locations[0].raw_source_name
locations[0].landing_page_url	https://doi.org/10.1158/1535-7163.c.6537472
indexed_in	crossref
authorships[0].author.id	https://openalex.org/A5100620486
authorships[0].author.orcid	https://orcid.org/0000-0001-9665-6642
authorships[0].author.display_name	Fei Huang
authorships[0].author_position	first
authorships[0].raw_author_name	Fei Huang
authorships[0].is_corresponding	False
authorships[1].author.id	https://openalex.org/A5106183263
authorships[1].author.orcid
authorships[1].author.display_name	Han Chang
authorships[1].author_position	middle
authorships[1].raw_author_name	Han Chang
authorships[1].is_corresponding	False
authorships[2].author.id	https://openalex.org/A5064430254
authorships[2].author.orcid	https://orcid.org/0000-0002-3625-4921
authorships[2].author.display_name	Ann Greer
authorships[2].author_position	middle
authorships[2].raw_author_name	Ann Greer
authorships[2].is_corresponding	False
authorships[3].author.id	https://openalex.org/A5074260221
authorships[3].author.orcid
authorships[3].author.display_name	Stephen Hillerman
authorships[3].author_position	middle
authorships[3].raw_author_name	Stephen Hillerman
authorships[3].is_corresponding	False
authorships[4].author.id	https://openalex.org/A5089007791
authorships[4].author.orcid
authorships[4].author.display_name	Karen A. Reeves
authorships[4].author_position	middle
authorships[4].raw_author_name	Karen A. Reeves
authorships[4].is_corresponding	False
authorships[5].author.id	https://openalex.org/A5005258847
authorships[5].author.orcid
authorships[5].author.display_name	Warren Hurlburt
authorships[5].author_position	middle
authorships[5].raw_author_name	Warren Hurlburt
authorships[5].is_corresponding	False
authorships[6].author.id	https://openalex.org/A5075325828
authorships[6].author.orcid
authorships[6].author.display_name	John Cogswell
authorships[6].author_position	middle
authorships[6].raw_author_name	John Cogswell
authorships[6].is_corresponding	False
authorships[7].author.id	https://openalex.org/A5057910121
authorships[7].author.orcid	https://orcid.org/0000-0002-8474-6453
authorships[7].author.display_name	Dharmesh Patel
authorships[7].author_position	middle
authorships[7].raw_author_name	Dharmesh Patel
authorships[7].is_corresponding	False
authorships[8].author.id	https://openalex.org/A5054751329
authorships[8].author.orcid
authorships[8].author.display_name	Zhenhao Qi
authorships[8].author_position	middle
authorships[8].raw_author_name	Zhenhao Qi
authorships[8].is_corresponding	False
authorships[9].author.id	https://openalex.org/A5113601750
authorships[9].author.orcid
authorships[9].author.display_name	Craig Fairchild
authorships[9].author_position	middle
authorships[9].raw_author_name	Craig Fairchild
authorships[9].is_corresponding	False
authorships[10].author.id	https://openalex.org/A5109566735
authorships[10].author.orcid
authorships[10].author.display_name	Rolf-Peter Ryseck
authorships[10].author_position	middle
authorships[10].raw_author_name	Rolf-Peter Ryseck
authorships[10].is_corresponding	False
authorships[11].author.id	https://openalex.org/A5104110277
authorships[11].author.orcid
authorships[11].author.display_name	Tai W. Wong
authorships[11].author_position	middle
authorships[11].raw_author_name	Tai W. Wong
authorships[11].is_corresponding	False
authorships[12].author.id	https://openalex.org/A5106120955
authorships[12].author.orcid
authorships[12].author.display_name	Friedrich Graf Finckenstein
authorships[12].author_position	middle
authorships[12].raw_author_name	Friedrich G. Finckenstein
authorships[12].is_corresponding	False
authorships[13].author.id	https://openalex.org/A5108495269
authorships[13].author.orcid
authorships[13].author.display_name	Jeffrey R. Jackson
authorships[13].author_position	middle
authorships[13].raw_author_name	Jeffrey Jackson
authorships[13].is_corresponding	False
authorships[14].author.id	https://openalex.org/A5088565265
authorships[14].author.orcid
authorships[14].author.display_name	Joan M. Carboni
authorships[14].author_position	last
authorships[14].raw_author_name	Joan M. Carboni
authorships[14].is_corresponding	False
has_content.pdf	False
has_content.grobid_xml	False
is_paratext	False
open_access.is_oa	True
open_access.oa_url	https://doi.org/10.1158/1535-7163.c.6537472
open_access.oa_status	gold
open_access.any_repository_has_fulltext	False
created_date	2025-10-10T00:00:00
display_name	Data from <i>IRS2</i> Copy Number Gain, <i>KRAS</i> and <i>BRAF</i> Mutation Status as Predictive Biomarkers for Response to the IGF-1R/IR Inhibitor BMS-754807 in Colorectal Cancer Cell Lines
has_fulltext	False
is_retracted	False
updated_date	2025-11-06T03:46:38.306776
primary_topic.id	https://openalex.org/T11067
primary_topic.field.id	https://openalex.org/fields/27
primary_topic.field.display_name	Medicine
primary_topic.score	0.9811999797821045
primary_topic.domain.id	https://openalex.org/domains/4
primary_topic.domain.display_name	Health Sciences
primary_topic.subfield.id	https://openalex.org/subfields/2730
primary_topic.subfield.display_name	Oncology
primary_topic.display_name	Colorectal Cancer Treatments and Studies
related_works	https://openalex.org/W3030972949, https://openalex.org/W4283712951, https://openalex.org/W2082860237, https://openalex.org/W4229832877, https://openalex.org/W4306404900, https://openalex.org/W3111812619, https://openalex.org/W4248366929, https://openalex.org/W2590035663, https://openalex.org/W2914997899, https://openalex.org/W4229670017
cited_by_count	0
locations_count	1
best_oa_location.id	doi:10.1158/1535-7163.c.6537472
best_oa_location.is_oa	True
best_oa_location.source
best_oa_location.license	cc-by
best_oa_location.pdf_url
best_oa_location.version	acceptedVersion
best_oa_location.raw_type	posted-content
best_oa_location.license_id	https://openalex.org/licenses/cc-by
best_oa_location.is_accepted	True
best_oa_location.is_published	False
best_oa_location.raw_source_name
best_oa_location.landing_page_url	https://doi.org/10.1158/1535-7163.c.6537472
primary_location.id	doi:10.1158/1535-7163.c.6537472
primary_location.is_oa	True
primary_location.source
primary_location.license	cc-by
primary_location.pdf_url
primary_location.version	acceptedVersion
primary_location.raw_type	posted-content
primary_location.license_id	https://openalex.org/licenses/cc-by
primary_location.is_accepted	True
primary_location.is_published	False
primary_location.raw_source_name
primary_location.landing_page_url	https://doi.org/10.1158/1535-7163.c.6537472
publication_date	2023-04-03
publication_year	2023
referenced_works_count	0
abstract_inverted_index.1	4
abstract_inverted_index.2	120
abstract_inverted_index.a	41
abstract_inverted_index.60	49
abstract_inverted_index.In	106, 216
abstract_inverted_index.an	10
abstract_inverted_index.as	209, 235
abstract_inverted_index.at	9
abstract_inverted_index.by	211
abstract_inverted_index.if	91
abstract_inverted_index.in	20, 48, 195, 205, 251
abstract_inverted_index.is	213
abstract_inverted_index.of	39, 81, 99, 104, 146, 149, 193, 202
abstract_inverted_index.or	71, 101, 126
abstract_inverted_index.to	61, 89, 134, 165, 171, 185, 241, 257
abstract_inverted_index.we	55, 218
abstract_inverted_index.AKT	166
abstract_inverted_index.CNG	142, 204
abstract_inverted_index.RNA	96, 226
abstract_inverted_index.The	63, 200
abstract_inverted_index.and	84, 151, 182, 224, 229, 231
abstract_inverted_index.are	7, 28, 168
abstract_inverted_index.for	25, 30, 189, 239, 249
abstract_inverted_index.had	143
abstract_inverted_index.low	15
abstract_inverted_index.the	14, 108, 135, 190, 197
abstract_inverted_index.35%.	215
abstract_inverted_index.AKT,	152
abstract_inverted_index.CNG,	221
abstract_inverted_index.IR-A	100
abstract_inverted_index.IRS2	174, 178, 194
abstract_inverted_index.This	243
abstract_inverted_index.both	82
abstract_inverted_index.cell	53, 67, 77, 109, 138, 156
abstract_inverted_index.copy	122
abstract_inverted_index.drug	198
abstract_inverted_index.dual	42
abstract_inverted_index.gain	124
abstract_inverted_index.have	93
abstract_inverted_index.more	132, 162, 169
abstract_inverted_index.seen	19
abstract_inverted_index.that	66, 154
abstract_inverted_index.they	92
abstract_inverted_index.were	74, 86, 131
abstract_inverted_index.with	45, 59, 69, 79, 111, 115, 140, 158, 254
abstract_inverted_index.work	244
abstract_inverted_index.(CNG)	125
abstract_inverted_index.IR-A,	223
abstract_inverted_index.Ther;	263
abstract_inverted_index.drug.	136
abstract_inverted_index.given	13
abstract_inverted_index.human	50
abstract_inverted_index.lines	68, 78, 110, 139, 157
abstract_inverted_index.lower	102
abstract_inverted_index.rates	18
abstract_inverted_index.siRNA	175
abstract_inverted_index.these	155
abstract_inverted_index.those	114
abstract_inverted_index.14(2);	264
abstract_inverted_index.Cancer	262
abstract_inverted_index.IGF-1R	128, 150
abstract_inverted_index.IGF-IR	159
abstract_inverted_index.IGFBP6	225
abstract_inverted_index.cancer	52, 207, 253
abstract_inverted_index.either	94, 116
abstract_inverted_index.factor	2
abstract_inverted_index.growth	1
abstract_inverted_index.higher	95, 127, 144
abstract_inverted_index.levels	98, 103, 145, 181
abstract_inverted_index.lines,	54
abstract_inverted_index.number	123
abstract_inverted_index.showed	65
abstract_inverted_index.status	234
abstract_inverted_index.tumors	208
abstract_inverted_index.©2014	266
abstract_inverted_index.IGF-1R,	222
abstract_inverted_index.IGFBP6.	105
abstract_inverted_index.coupled	164
abstract_inverted_index.genomic	46
abstract_inverted_index.improve	258
abstract_inverted_index.insulin	117
abstract_inverted_index.levels,	130, 228
abstract_inverted_index.patient	26, 255
abstract_inverted_index.protein	179
abstract_inverted_index.reduced	177
abstract_inverted_index.results	64
abstract_inverted_index.testing	38
abstract_inverted_index.whereas	76
abstract_inverted_index.Coupling	34
abstract_inverted_index.actively	163
abstract_inverted_index.benefit.	33, 260
abstract_inverted_index.clinical	16, 32, 246, 259
abstract_inverted_index.critical	29
abstract_inverted_index.evidence	188
abstract_inverted_index.measured	210
abstract_inverted_index.mutation	73
abstract_inverted_index.pathways	161
abstract_inverted_index.proposed	245
abstract_inverted_index.qPCR-CNV	212
abstract_inverted_index.receptor	3, 118
abstract_inverted_index.response	17, 60, 240
abstract_inverted_index.summary,	217
abstract_inverted_index.620–30.	265
abstract_inverted_index.IGF-1R/IR	43, 172
abstract_inverted_index.addition,	107
abstract_inverted_index.candidate	236
abstract_inverted_index.crossroad	12
abstract_inverted_index.currently	8
abstract_inverted_index.decreased	183
abstract_inverted_index.important	11
abstract_inverted_index.improving	31
abstract_inverted_index.knockdown	176
abstract_inverted_index.mediating	196
abstract_inverted_index.patients.	22
abstract_inverted_index.providing	187
abstract_inverted_index.response.	199
abstract_inverted_index.selection	27, 256
abstract_inverted_index.sensitive	88, 133
abstract_inverted_index.signaling	160, 167
abstract_inverted_index.substrate	119
abstract_inverted_index.therapies	6
abstract_inverted_index.wild-type	80
abstract_inverted_index.BMS-754807	90, 250
abstract_inverted_index.Predictive	23
abstract_inverted_index.activation	148
abstract_inverted_index.biomarkers	24, 57, 238
abstract_inverted_index.colorectal	51, 206, 252
abstract_inverted_index.correlated	58
abstract_inverted_index.expression	97, 129, 180, 227
abstract_inverted_index.functional	191
abstract_inverted_index.identified	56, 219
abstract_inverted_index.inhibitor,	44
abstract_inverted_index.mutational	233
abstract_inverted_index.mutations,	113
abstract_inverted_index.predictive	237
abstract_inverted_index.prevalence	201
abstract_inverted_index.resistant,	75
abstract_inverted_index.responsive	170
abstract_inverted_index.suggesting	153
abstract_inverted_index.unselected	21
abstract_inverted_index.<i>in	35
abstract_inverted_index.BMS-754807,	40, 186
abstract_inverted_index.BMS-754807.	62, 242
abstract_inverted_index.development	247
abstract_inverted_index.inhibition.	173
abstract_inverted_index.involvement	192
abstract_inverted_index.sensitivity	37, 184
abstract_inverted_index.<i>Mol	261
abstract_inverted_index.Furthermore,	137
abstract_inverted_index.particularly	87
abstract_inverted_index.approximately	214
abstract_inverted_index.opportunities	248
abstract_inverted_index.interrogations	47
abstract_inverted_index.vitro</i>	36
abstract_inverted_index.ligand-stimulated	147
abstract_inverted_index.(IGF-1R)–targeting	5
abstract_inverted_index.<i>BRAF</i>	85, 232
abstract_inverted_index.<i>IRS2</i>	141, 203, 220
abstract_inverted_index.<i>KRAS</i>	83, 112, 230
abstract_inverted_index.(<i>IRS2</i>)	121
abstract_inverted_index.AACR</i>.</p></div>	267
abstract_inverted_index.<div>Abstract<p>Insulin-like	0
abstract_inverted_index.<i>KRAS</i><sup>G13D</sup>	72
abstract_inverted_index.<i>BRAF</i><sup>V600E</sup>	70
cited_by_percentile_year
countries_distinct_count	0
institutions_distinct_count	15
sustainable_development_goals[0].id	https://metadata.un.org/sdg/3
sustainable_development_goals[0].score	0.6000000238418579
sustainable_development_goals[0].display_name	Good health and well-being
citation_normalized_percentile.value	0.55986509
citation_normalized_percentile.is_in_top_1_percent	False
citation_normalized_percentile.is_in_top_10_percent	False

Data from <i>IRS2</i> Copy Number Gain, <i>KRAS</i> and <i>BRAF</i> Mutation Status as Predictive Biomarkers for Response to the IGF-1R/IR Inhibitor BMS-754807 in Colorectal Cancer Cell Lines Article Swipe

Related Topics

Raw OpenAlex JSON

Full payload